Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
NCT00005652
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
DRUG:
rituximab
Sponsor
University of Alabama at Birmingham